Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozymes IX and XII with polyfluorinated aromatic/heterocyclic sulfonamides

Silvia Pastorekova, Daniela Vullo, Angela Casini, Andrea Scozzafava, Jaromir Pastorek, Isao Nishimori, Claudiu T. Supuran

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

The tumor-associated transmembrane carbonic anhydrase (CA, EC 4.2.1.1) isozymes IX (CA IX) and XII (CA XII) are involved in acidification of hypoxic tumors, a process correlated with poor prognosis and clinical outcome of patients harboring such tumors. This process may be reversed by inhibiting these enzymes with potent sulfonamide/sulfamate inhibitors. A series of such aromatic/heterocyclic sulfonamides incorporating 2,3,5,6-tetrafluorobenzoyl-, 2,3,5,6-tetrafluorophenylsulfonyl- and pentafluorophenylureido moieties has been investigated for its interaction with the catalytic domain of the human isozymes hCA IX and hCA XII. Some of these compounds showed excellent inhibitory properties against both isozymes IX and XII, with several subnanomolar inhibitors detected for the first time. These sulfonamides may constitute valuable candidates for the development of novel antitumor therapies based on the inhibition of such tumor-associated CA isozymes.

Original languageEnglish
Pages (from-to)211-217
Number of pages7
JournalJournal of Enzyme Inhibition and Medicinal Chemistry
Volume20
Issue number3
DOIs
StatePublished - Jun 2005
Externally publishedYes

Keywords

  • Antitumor drug
  • Carbonic anhydrase
  • Inhibitors
  • Isozymes IX and XII
  • Polyfluorinated derivative
  • Sulfonamide

Fingerprint

Dive into the research topics of 'Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozymes IX and XII with polyfluorinated aromatic/heterocyclic sulfonamides'. Together they form a unique fingerprint.

Cite this